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The antigens recognized by individual CD8 T cells are small peptides bound to major histocompatibility complex (MHC) class
I molecules. The CD8 T cell response to a virus is restricted to several peptides, and the magnitudes of the effector as well as
memory phases of the response to the individual peptides are generally hierarchical. The peptide eliciting a stronger response is
called immunodominant (ID), and those with smaller-magnitude responses are termed subdominant (SD). The relative impor-
tance of ID and SD determinants in protective immunity remains to be fully elucidated. We previously showed that multispecific
memory CD8 T cells can protect susceptible mice frommousepox, an acute lethal viral disease. It remained unknown, however,
whether CD8 T cells specific for single ID or SD peptides could be protective. Here, we demonstrate that immunization with
dendritic cells pulsed with ID and some but not all SD peptides induces memory CD8 T cells that are fully capable of protecting
susceptible mice frommousepox. Additionally, while natural killer (NK) cells are essential for the natural resistance of nonim-
mune C57BL/6 (B6) to mousepox, we show that memory CD8 T cells of single specificity also protect B6 mice depleted of NK
cells. This suggests it is feasible to produce effective antiviral CD8 T cell vaccines using single CD8 T cell determinants and
that NK cells are no longer essential whenmemory CD8 T cells are present.
During viral infections, viral proteins are degraded by the pro-teolytic machinery of the cell into small peptides. Peptides
with the appropriate motif and that are 8 to 10 amino acids long
bind tomajor histocompatibility class I (MHC-I)molecules in the
endoplasmic reticulum and are transported to the cell surface for
presentation to CD8 T cells, which use clonotypic T cell recep-
tors (TCR) encodedby somatically recombined genes to recognize
specific MHC-I-bound peptides, also known as determinants (1).
Themagnitude of the CD8T cell response to the variousMHC-I
determinants of a virus is generally hierarchical, a phenomenon
called T cell immunodominance (59, 60). The determinant that
elicits the highest number of CD8 T cells is termed immuno-
dominant (ID), and those that induce smaller but detectable re-
sponses are known as subdominant (SD). Some peptides may
bind to MHC-I molecules but be ignored by the CD8 T cell
response. Immunodomination is the result of many interacting
factors affecting antigen-presenting cells (APC), such as antigen
processing and presentation, and T cells, such as differences in
precursor frequency, T cell receptor affinity, competition for ac-
tivating stimuli, etc. (59, 60).
At the peak of an antiviral response, the frequency of virus-
specific CD8T cells can be as high as 60 to 80%of the total CD8
T cells (13, 38). These cells produce effector molecules, such as
gamma interferon (IFN-), which has antiviral and immuno-
modulatory effects, and perforin (Prf) and granzyme B (GzB),
which kill infected cells through granule exocytosis. If the virus is
controlled, 90% of the antiviral CD8 T cells die, but some
remain asmemoryCD8T cells (38). In the resting state,memory
CD8 T cells do not express effector molecules. However, upon
antigen encounter, they rapidly become effectors and proliferate.
In this way, they help to quickly control secondary infection by the
same or similar viruses. It is thought that memory CD8 T cells
play an important role in vaccine protection, and there is a strong
impetus in designing new vaccines that induce protective antiviral
CD8 T cell memory. Therefore, it is of interest to determine the
level of protection that can be conferred by memory CD8 T cells
specific for ID or SD determinants during a lethal viral infection.
It has been reported that peptide-dendritic cell (DC) vaccina-
tion with a Listeria monocytogenes ID determinant reduced bacte-
rial burden (3). It has also been shown that immunization with
recombinant vaccinia virus (VACV) expressing various lympho-
cytic choriomeningitis virus (LCMV) determinants protected
mice from lethal intracranial LCMV challenge infection (28, 29,
56). In addition, the same VACV recombinants (41) and DNA
vaccines expressing the LCMV nucleoprotein (NP) containing an
ID determinant (34) protectedmice from chronic LCMVclone 13
infection administered intravenously (i.v.). Presently, it remains
unknown whether memory CD8 T cells specific for single ID or
SD determinants can protect from a lethal acute systemic viral
infection that spreads via the lympho-hematogenous route in its
natural host.
Natural killer (NK) cells are cells of the innate immune system
that are essential for resistance to several primary viral infections
(9, 10, 25, 26, 43). Similar to CD8 T cells, their main effector
Received 19 April 2012 Accepted 22 June 2012
Published ahead of print 27 June 2012
Address correspondence to Luis J. Sigal, Luis.Sigal@fccc.edu.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.00981-12
9748 jvi.asm.org Journal of Virology p. 9748–9759 September 2012 Volume 86 Number 18
mechanism are the production of IFN- and killing of infected
cells by granule exocytosis (5, 7, 18, 22, 32). Different from CD8
T cells, however, NK cells recognize infected cells using germ line-
encoded activating receptors rather than antigen-specific recep-
tors (30). Because NK cells do not need to expand clonotypically,
they can contribute to virus control during the first few days of
infection, when the adaptive response is still incipient. Because
their effector functions overlap, it remains possible that NK cells
are no longer required when antiviral memory CD8 T cells are
present at relatively high frequencies; however, this possibility has
not been thoroughly explored.
Orthopoxviruses (OPV) are a genus of highly conserved DNA
viruses that includes, among others, variola virus, the causative
agent of smallpox in humans, VACV, the virus used as the small-
pox vaccine, and ectromelia virus (ECTV), the causative agent of
mousepox inmice (16).Different fromVACV,which is often used
as the prototypic OPV, ECTV naturally infects the mouse. When
inoculatedwith as little as 1 PFU in the footpad, its natural route of
infection, ECTV causes disease and death in susceptible mouse
strains, including BALB/c (H-2d) (54) and B6.D2-(D6Mit149-
D6Mit15)/LusJ, a congenic strain of C57BL/6 (B6) that carries the
distal portion of chromosome 6 of the susceptible DBA/2J strain,
and referred to here as B6.D2-D6 (H-2b) (11, 15). On the other
hand, B6 mice are naturally resistant to mousepox but become
susceptible if depleted ofNK cells before or soon after infection (9,
10, 43).
We have previously shown that memory CD8 T cells can
protect susceptible mice from lethal mousepox (58). Therefore,
ECTV infection of susceptible mice serves as a model to under-
stand themechanisms of CD8 T cell protective immunity.Work
by others has shown that the sequence of the IDH-2 Kb-restricted
determinant TSYKFESV (amino acids 20 to 27 of the B8Rprotein)
of VACV is fully conserved in ECTV (48). We found that several
SDdeterminants of VACV are also fully conserved and serve as SD
determinants in ECTV. Armed with this knowledge, we immu-
nized susceptible B6.D2-D6 mice with DCs pulsed with the ID or
SDpeptides.We found that thismethodof immunization resulted
in the induction of a high frequency of memory CD8 T cells to
some but not all the peptides. B6.D2-D6 mice immunized with
those peptides that successfully induced high frequencies ofmem-
ory CD8 T cells were protected from mousepox, regardless of
their immunodominance hierarchy during infection. Addition-
ally, we found that B6 mice immunized with TSYKFESV-pulsed
DCs remained resistant to mousepox after NK cell depletion (10,
25, 43), suggesting that when memory CD8 T cells are present,
NK cells may no longer be required for resistance to viral diseases.
Our findings are important for a thorough understanding of the
mechanisms of protective T cell immunity and for the rational
development of CD8 T cell vaccines.
MATERIALS AND METHODS
Ethics statement. All experiments were performed following guidelines
of the National Institutes of Health. The Fox Chase Cancer Center
(FCCC) Institutional Animal Care and Use Committee approved the ex-
perimental protocols involving animals.
Viruses. Initial stocks of the wild-type (WT) ECTV Moscow (6, 15)
were obtained from ATCC (VR-1374). New stocks of ECTV WT were
expanded in BS-C-1 cells infected with 0.1 PFU/cell as described previ-
ously (57). Briefly, BS-C-1 cells in T150 flasks were infected with 0.1
PFU/cell. After 3 or 4 days cells were collected, resuspended in phosphate-
buffered saline (PBS), frozen and thawed three times, and stored in ali-
quots at 80°C as virus stock. Virus titers in ECTV stocks were deter-
mined by plaque assays on confluent BS-C-1 cells by using 10-fold serial
dilutions of the stocks in 0.5 ml Dulbecco’s modified Eagle’s medium
(DMEM)–2.5% fetal bovine serum (FBS) in 6-well plates (2 wells/dilu-
tion) for 1 h. Twomilliliters of freshDMEM–2.5%FBSwas added, and the
cells were incubated at 37°C for 5 days. Next, the medium was aspirated
and the cells were fixed for 1 h with 3.7% paraformaldehyde, washed with
water, and stained with 0.1% crystal violet in 20% ethanol. The fix/stain
solution was subsequently aspirated, the cells air dried, the plaques
counted, and PFU/ml values in stocks were calculated accordingly.
For the determination of virus titers in spleens, the spleens were re-
moved from experimental mice on the indicated days after footpad infec-
tion, made into a single-cell suspension between two frosted slides, and
resuspended in 10 ml complete RPMImedium. One-milliliter aliquots of
the cell suspensions were frozen and thawed three times, and titers were
determined in 10-fold serial dilutions of the cell lysates as described above.
Virus titers were calculated as PFU/spleen. To determine the virus titers in
liver, a portion of the liver was weighed and homogenized in medium by
using a tissue lyser (Qiagen). The virus titers were calculated as PFU/gram
of liver.
Mice and infections. The Fox Chase Cancer Center Institutional An-
imal Care and Use Committee approved the experimental protocols in-
volving animals. C57BL/6 mice were purchased from Taconic when they
were 8 to 10 weeks of age and were rested at least a week before use in
experiments. The B6.D2-(D6Mit149-D6Mit15)/LusJ (B6.D2-D6) mice
were initially purchased from Jackson Laboratory and bred in the Fox
Chase Cancer Center Laboratory Animal Facility. Unless indicated, mice
were infectedwith ECTV in the left footpadwith 25l PBS containing 3
103 PFU. Following infections, mice were observed daily for signs of dis-
ease (lethargy, ruffled hair, weight loss, skin rash, eye secretions) and
imminent death (unresponsiveness to touch, lack of voluntary move-
ments).
In vivo cytotoxicity assays. In vivo cytotoxicity assays were performed
as described elsewhere (14). Briefly, red blood cell-depleted splenocytes
from naïve B6 mice were split into two populations. One population was
labeled with a high concentration of carboxyfluorescein succinimidyl-
ester (CFSE) at 4 M (CFSEhigh) and pulsed with SIINFEKL or a VACV/
ECTV determinant, TSYKFESV (B8R20–27), SIFRFLNI (J3R289–296), KSY
NYMLL (A3L270–277), ITYRFYLI (A8R189–196), or STLNFNNL
(E7R130–137) (GenScript) at a final concentration of 1 g/ml. For in vivo
cytotoxicity assays in DC-vaccinated memory mice, the second popula-
tion of lymphocytes was labeled with a low concentration of CFSE (0.8
M; CFSElow) and was pulsed with the SIINFEKL peptide at a final con-
centration of 1 g/ml. The two cell populations were mixed together in a
1:1 ratio, and 2 107 cells were injected i.v. into naïve or ECTV-infected
B6 mice or naïve or DC-vaccinated memory mice. For naïve and ECTV-
infected B6 recipient and naïve and DC-vaccinated memory mice, at 4 h
and 18 h, respectively, after target cell inoculation, the recipientmice were
sacrificed and the presence of CFSElow and CFSEhigh cells was determined
by flow cytometry in cell suspensions of lymph nodes and spleens from
individual mice. To calculate the percent specific lysis, the following for-
mula was used: [1 (ratio for unprimed/ratio for primed)] 100, where
the ratio for unprimed and primed were calculated as the percent
CFSElow/percent CFSEhigh (21).
Histopathology. Livers were aseptically collected, and 0.5- to 1.0-g
liver sections were fixed in formalin and embedded in paraffin blocks.
Serial sections were stained with hematoxyl and eosin (H&E) or immu-
nostained with EVM135.
Bonemarrow-derived dendritic cells and vaccination.Wegenerated
bone marrow-derived CD11c DCs in the presence of granulocyte-mac-
rophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) as
described previously (23). Lipopolysaccharide (100 ng/ml; Sigma) was
added on the last day to inducematuration. After 5 to 7 days in culture, the
cells were collected, incubated for 1 h with 1 g peptide, washed exten-
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sively, and resuspended in PBS (2 106 cells/ml), and 500 l was inocu-
lated i.v. into recipient mice.
Flow cytometry. Detection of T cell responses was performed as de-
scribed previously (12–14, 58). Briefly, spleens frommice were made into
single-cell suspensions, and the red blood cells were lysed in 0.84%
NH4Cl. Liver-infiltrating mononuclear cells were separated by centrifu-
gation over 36%Percoll (GEHealthcare). Cells were washed, and 106 cells
were cultured at 37°C in 96-well plates. For each sample, 2 106 cells were
incubated with no peptide or 0.1 g/ml TSYKFESV, SIFRFLNI, or SIIN
FEKL for restimulation in the presence of brefeldin A (BFA; Sigma) and
monensin (Golgi plug; Becton, Dickinson [BD]). After 2 h, 0.4 g of
CD107a antibody (Ab; Biolegend) was added to measure degranulation.
After a total of 5 h of restimulation, supernatant of Ab 2.4G2 (anti-Fc
II/III receptor; ATCC) was added to block nonspecific binding of labeled
Ab to Fc receptors. The cells were then stained for cell surface molecules,
fixed, permeabilized, and stained for intracellular molecules by using the
Cytofix/Cytoperm kit (BD) according to themanufacturer’s instructions.
The following Abs were used: anti-CD3 (145-2C11; Biolegend), anti-CD4
(GK1.5; Biolegend), anti-CD8a (53-6.7; Biolegend), anti-IFN- (clone
XMG1.2; Biolegend), anti-CD14 (Sa14-2; Biolegend), anti-CD16 (93;
Biolegend), anti-CD19 (6D5; Biolegend), anti-CD107a (1D4B; Bioleg-
end), and phycoerythrin-Cy5.5-labeled anti-human GzB (Caltag), which
cross-reacts with mouse GzB (57). For VACV/ECTV- and SIINFEKL-
specific CD8 T cells, H-2 Kb:Ig recombinant fusion protein (Dimer-X;
BD) was incubated with synthetic TSYKFESV, ITYRFYLI, SIFRFLNI, KS
YNYMLL, and SIINFEKL peptides and used as recommended by the
manufacturer. On some occasions, instead of Kb-peptide dimers, we used
Kb-TSYKFESV, -SIFRFLNI, -KSYNYMLL, and -STLNFNNL tetramers
prepared by theNIAIDTetramer Facility or Kb-TSYKFESVor -SIINFEKL
tetramers prepared in our laboratory according to published methods
(47). Stained cells were analyzed by flow cytometry at the Fox Chase Cell
Sorting Facility using an LSR II system (BD). At least 100,000 cells were
analyzed.
Data display and statistical analysis. Unless indicated, all displayed
data correspond to one representative experiment of at least two similar
experiments with groups of three to six mice. Spleens and livers were
analyzed individually, and results are representative of at least two inde-
pendent experiments. Statistical analysis was performed using GraphPad
Prism software. For survival studies, P values were obtained using the
log-rank (Mantel-Cox) test. All other statistical analyses were performed
using an unpaired two-tailed t test or theMann-Whitney test as necessary.
When applicable, data are displayed with means standard error of the
means (SEM). P values were determined between SIINFEKL-immunized
or TSYKFESV-immunizedmice and all other groups. Data were analyzed
to P levels of 0.05, 0.01, and 0.001, as shown in the figures and described in
the figure legends below (when not marked in the figures, the differences
were not statistically significant).
RESULTS
Identification of H-2 Kb-restricted ECTV determinants. By us-
ing intracellular staining for IFN-, we and others previously
identified 49 determinants that account for the majority (94.8%)
of the CD8 T cell response to VACV Western Reserve (WR) in
B6 mice (36, 48, 61). Of interest, the ID determinant TSYKFESV
has been shown to be fully conserved and a major determinant in
ECTV (36, 61). When we compared sequences, we found that the
amino acids of 37 VACV SD determinants (36) were fully con-
served in ECTV. At least several of these peptides were ECTV
determinants, because a significant proportion of CD8 T lym-
phocytes from ECTV-infected B6mice were stained with Kb mul-
timers loaded with the conserved VACV SD peptides SIFRFLNI,
KSYNYMLL, ITYRFYLI, and STLNFNNL, albeit at a lower fre-
quency thanwhen loadedwith TSYKFESV (Fig. 1A and B). Also, 4
h after inoculation into ECTV-infected B6 mice, splenocytes
pulsed with any of the SD peptides were killed significantly less
than when pulsed with TSYKFESV but significantly more than
when pulsed with the control SIINFEKL (Fig. 1C and D). Thus,
while less pronounced, probably due to the kinetics of the assay,
the in vivo cytotoxicity results were consistent with those of Kb
multimer staining.
Variable responses to immunization with DCs pulsed with
ECTV/VACV CD8 T cell determinant peptides. Mousepox-
susceptible B6 congenic B6.D2-D6 mice were immunized and
boosted (1 week apart) with DCs pulsed with various ECTV/
VACV peptides or the control, SIINFEKL. Four weeks after boost,
CD8 T cells specific for the different peptides were identified by
staining with Kbmultimers loaded with the relevant peptides (Fig.
2A). ImmunizationwithDCs pulsedwith IDTSYKFESV aswell as
SD KSYNYMLL and SIFRFLNI, or control SIINFEKL, resulted in
similarly high numbesrof Kb-peptide-specific memory CD8 T
cells. On the other hand, immunization with DCs pulsed with SD
ITYRFYLI or STLNFNNLdid not result in a significant increase in
the frequency of cells that stained with the specific Kb-peptide
complexes (Fig. 2B). When we performed in vivo cytotoxicity as-
says (14) in draining lymph nodes (D-LN) and spleen, there was
some significant killing in mice immunized with ITYRFYLI-DC
(which did not induce a significant proportion of specificmemory
CD8 T cells as detected by Kb-multimer staining), but this was
significantly much lower than in mice immunized with TSYKFES
V-DC or SIFRFLNI-DC (Fig. 2C to E). Therefore, the number of
CD8 T cells induced by peptide-pulsed DC immunization varies
with the immunizing peptide, and the killing efficiency in vivo is
affected by the frequency of memory CD8 T cells that each pep-
tide induces and by other unknown factors.
Memory CD8 T cells elicited by immunization with pep-
tide-pulsed DCs respond to ECTV infection. B6.D2-D6 mice
were immunized and boosted with DCs pulsed with TSYKFESV,
SIFRFLNI, or SIINFEKL as a control. SD SIFRFLNI was chosen
for comparison with ID TSYKFESV, because it induced compara-
ble frequencies of Kb-peptide-specific memory CD8 T cells (Fig.
2A and B). Six to 8 weeks after boosting, the mice were infected
with ECTV, and 7 days postinfection (dpi) the CD8 T cell re-
sponses were examined in the livers (the main target organ of
ECTV) and spleens (Fig. 3). Consistent with our previous finding
that naive B6.D2-D6 mice do not mount CD8 T cell responses
when challenged with WT ECTV (11), none of the SIINFEKL-
immunized mice mounted a TSYKFESV or SIFRFLNI CD8 T
cell response in either the spleen or the liver. On the other hand,
mice immunized with DC-TSYKFESV had high frequencies and
absolute numbers of CD8 T cells that stained with Kb-TSYK
FESV (Fig. 3B and E), but only background numbers of cells that
stained with Kb-SIFRFLNI (Fig. 3C and F). In mice immunized
with DC-SIFRFLNI, Kb-SIFRFLNI (Fig. 3C and F) stained a high
proportion and high absolute numbers of CD8 T cells, but a
relatively high number of cells also stained with Kb-TSYKFESV
(Fig. 3B and E). This was not due to cross-reactivity, because each
cell stained with only one tetramer (Fig. 3A and D). Thus, in the
presence of memory cells to SD SIFRFLNI, a primary response to
the ID TSYKFESV was rescued, but not vice versa. Rescue of a
primary response by memory CD8 T cells after DC immuniza-
tion is consistent with our finding that adoptively transferred
memoryCD8T cells can rescue a primary response in otherwise-
unresponsive B6.D2-D6mice. This rescue of a primary response is
likely due to the ability of the memory cells to lower virus loads
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thereby preventing the death of naïve lymphocytes (S. Remakus et
al., submitted for publication).
We also analyzed the effector CD8 T cell responses after in
vitro restimulation with peptide. TSYKFESV restimulation re-
sulted in a significant increase in the frequency of CD8 T cells
expressing IFN- in liver mononuclear cells (Fig. 4A and C) and
splenocytes (Fig. 4B and D) from DC-TSYKFESV-immunized
mice. Similarly, SIFRFLNI restimulation of liver mononuclear
cells (Fig. 4A and C) and splenocytes (Fig. 4B and D) from DC-
SIFRFLNI-immunized mice resulted in a significantly increased
frequency of IFN- CD8 cells. CD8 T cells from the livers of
DC-SIINFEKL-immunized mice significantly upregulated IFN-
expression following restimulation with SIINFEKL, albeit to low
levels, likely because they did not expand (Fig. 4A and C). On the
other hand, SIINFEKL restimulation of splenocytes from DC-SII
NFEKL-immunizedmice did not result in a significant increase of
IFN- expression in CD8T cells (Fig. 4B andD), most likely due
to the severe lymphopenia that these close-to-death mice endure.
As we showed before (14), GzB expression is independent of pep-
tide restimulation and a marker of virus-specific CD8 T cell ef-
fectors. Accordingly, we found that DC-TSYKFESV and DC-SIF
RFLNI-immunized mice had a significantly higher proportion of
CD8T cells that expressed GzB thanDC-SIINFEKL-immunized
mice in both liver mononuclear cells (Fig. 4A and E) and spleno-
cytes (Fig. 4B and F). The relatively low proportion of cells pro-
ducing IFN- compared to Kb-peptide staining or GzB expression
is consistent with our previous report showing that themajority of
the ECTV-specific effector CD8 T cells do not produce IFN-
upon ex vivo restimulation (14). Together, these experiments
demonstrate that mousepox-susceptible B6.D2-D6 mice immu-
FIG 1 Identification ofH-2 Kb-restricted ECTVdeterminants. (A) B6mice were infected with 3,000 PFU of ECTV in the footpad, and splenocytes were analyzed
7 dpi. Representative flow cytometry plots show the frequencies of CD8 cells positive for H-2 Kb-TSYKFESV, -SIFRFLNI, -KSYNYMLL, -ITYRFYLI, and
-STLNFNNL. The dot plots represents the frequency of CD8 cells that were stained with the indicated Kb-peptide dimer in 3 independent experiments for all
peptides except for ITYRFYLI, for which data are from 2 independent experiments. (B) Graphs showing summary data of flow cytometry plots from panel A.
Open symbols represent naïve mice, and closed symbols represent ECTV-infected mice. Each data point corresponds to pooled splenocytes from 2 to 3 mice in
one experiment. (C) Representative in vivo cytotoxicity data. Naïve and VACV-immune mice were inoculated i.v. with a 1:1 mixture of B6 splenocytes labeled
with 0.8 MCFSE (CFSElow) or splenocytes labeled with 4 MCFSE and pulsed with the TSYKFESV (CFSEhigh). Mice were killed 4 h after target inoculation,
and the proportions of CFSElow and CFSEhigh cells were determined by flow cytometry in spleens of individual mice. Histograms are gated on CFSE-positive cells
of naïve and ECTV-infected B6mice, as indicated. (D) Summary of in vivo cytotoxicity assays using the indicated ECTV/VACVpeptide-pulsed targets. Numbers
indicate percentages of specific killing of CFSEhigh cells, calculated as detailed in Materials and Methods. Data correspond to means  SEM for 3 or more
independent experiments, where nwas 15 for TSYKFESV, nwas 12 for SIFRFLNI, nwas 12 for KSYNYMLL, nwas 10 for ITYRFYLI, nwas 3 for STLNFNNL, and
nwas 11 for SIINFEKL. P values (*, P 0.05; ***, P 0.001) shown were determined for comparisons TSYKFESV and all other groups. The P value determined
for SIINFEKL versus all other groups was0.001 (data not shown).
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nized with DCs pulsed with ID TSYKFESV or SD SIFRFLNI, but
not with irrelevant SIINFEKL, mount strong recall CD8 T cell
responses to ECTV. The results also showed thatmice immunized
with ID TSYKFESV do not mount a primary response to SD SIF
RFLNI (Fig. 3 and 4), while mice immunized with SD SIFRFLNI
mount a non-cross-reactive primary response to the ID TSYK
FESV (Fig. 3).
Productive peptide-DC immunization results in protective
immunity against lethal mousepox. B6.D2-D6mice primed and
boosted 6 to 8 weeks earlier with DCs pulsed with the ID TSYKF
ESV, SD SIFRFLNI, or ITYRFYLI (all of which induced a high
frequency of memory cells, as detected by Kb-peptide staining),
with SD KSYNYMLL or STLNFNNL (which did not induce a
significant number of memory CD8 T cells) or control SIIN
FEKL (which induced a high frequency of memory CD8 T cells
upon immunization but is not an ECTV determinant) were chal-
lenged with ECTV. All themice immunized with DCs pulsed with
ID TSYKFESV and SD SIFRFLNI survived the infection and lost
2% of their weight (Fig. 5A and B). Mice immunized with KSY
NYMLL-pulsedDCswere also highly protected, because 80% sur-
vived the infection and lost 10% of their weight. On the other
hand, all mice immunized with DCs pulsed with ITYRFYLI or
STLNFNNL (which did not generate a significant response), or
with SIINFEKL, succumbed to the infection and lost 10% of
their weight. Still, ITYRFYLI-DC immunization was somewhat
protective, because death was delayed by 4 days compared with
SIINFEKL immunized mice (Fig. 5A and B).
Next, we compared virus loads and pathology in protected
versus control unprotected mice. At 7 dpi, TSYKFESV- and SIFR
FLNI-immunized mice had significantly lower virus loads in the
spleen and liver than did SIINFEKL-immunizedmice (Fig. 5C and
D). Moreover, 7 dpi the livers of TSYKFESV- and SIFRFLNI-
immunized mice had significantly fewer necrotic foci than SIINF
EKL-immunized mice. Different from the foci in SIINFEKL-im-
FIG 2 Variable responses to immunization with DCs pulsed with ECTV/VACV peptides. (A) Representative flow cytometry plots of the frequencies of positive
Kb-TSYKFESV, -SIFRFLNI, -KSYNYML, -ITYRFYLI, -STLNFNNL, and -SIINFEKL CD8 PBMC obtained from B6.D2-D6 mice 1 month after peptide-DC
booster immunization. (B) Column graphs showing summary data of flow cytometry plots from panel A. Data correspond to 3 or more independent experi-
ments, with n 5 per group. (C) Representative in vivo cytotoxicity data of naïve and peptide-DC-immunizedmice (	2months after vaccination) that received
SIINFEKL-pulsed CFSElow cells (control) or ECTV peptide-pulsed CFSEhigh cells i.v. Mice were killed 18 h after target inoculation, and the proportions of
CFSElow and CFSEhigh cells were determined by flow cytometry in pooled LNs and spleens. Histograms are gated on CFSE-positive cells. Numbers indicate
percentages of specific killing of CFSEhigh cells, calculated as detailed inMaterials andMethods. (D and E) Column graphs showing summary data from panel C
in pooled LNs (D) and in spleens from individualmice (E).Data correspond to 5 vaccinatedmice per group the SEM.Data are representative of two (SIFRFLNI
and ITYRFLI) or three (TSYKFESV) experiments. All samples are compared to results for animals that receivedDC-SIINFEKL (*,P 0.05; **, P 0.01; ***, P
0.001), and where statistical differences are indicated, those groups were also significantly different from uninfected animals (data not shown).
Remakus et al.
9752 jvi.asm.org Journal of Virology
FIG 3 Memory CD8 T cells elicited by immunization with peptide-pulsed DCs are present in the liver and spleen after ECTV infection. B6.D2-D6 mice were
immunized with peptide-DC and 2 months later infected with 3,000 PFU of ECTV in the footpad. At 7 dpi, livers and spleens were analyzed in individual mice.
(A) Representative flow cytometry plots showing frequencies of CD8 cells in the livers that were Kb-TSYKFESV or Kb-SIFRFLNI. (B) Column graphs
correspond to summary data presented in the flow cytometry plots of panel A. Frequencies and absolute numbers of positive CD8 cells are shown for mice
immunized with Kb-TSYKFESV as indicated. Data correspond to five mice per group the SEM and are representative of two independent experiments. (C)
Summary data as described for panel B, but showing the frequencies and absolute numbers of CD8 cells that were Kb-SIFRFLNI. (D) Representative flow
cytometry plots showing frequencies of CD8 cells that were Kb-TSYKFESV or Kb-SIFRFLNI in the spleen. (E) Column graphs corresponding to summary
data for the frequencies of CD8 cells that were Kb-TSYKFESV. Data correspond to results for five mice per group  SEM and are representative of two
independent experiments. (F) Summary data as described for panel B, but for Kb-SIFRFLNI cells. *, P 0.05; **, P 0.01; ***, P 0.001.
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FIG 4 Memory CD8 T cells elicited by immunization with peptide-pulsed DCs become activated in the liver and spleen in response to ECTV infection.
B6.D2-D6mice were immunized with DCs pulsed with the indicated peptides and 2months later infected with 3,000 PFU of ECTV in the footpad. (A and B) At
7 dpi, livers and spleens were analyzed in individualmice. Representative flow cytometry dot plots are shown for IFN- andGzB expression in livermononuclear
cells (A) and splenocytes (B). The top row shows control unimmunized, uninfected mice. All graphs are gated on CD8 CD4 cells. (C to F) Graphs show the
summary data for the frequencies of CD8 T cells expressing IFN- (C and D) or GzB (E and F) in the livers and spleens. Data correspond to five mice per
group the SEM and are representative of two independent experiments. *, P 0.05; **, P 0.01; ***, P 0.001.
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FIG 5 Productive peptide-DC immunization results in protective immunity against lethal mousepox infection. B6.D2-D6 mice were immunized and boosted
(1 week apart) with the indicated peptide-DC dimer and challenged more than 1 month later with 3,000 PFU of ECTV in the footpad. (A) Survival curve of
B6.D2-D6mice. The experiment is representative of three, with n of 5 per group. (B) Body weights over the course of infection. Data are expressed as the percent
initial weight the SEM. (C and D) Virus titers in spleen and liver, respectively. Data correspond to 5 mice per group SEM and are representative of three
independent experiments. (E) Liver histopathology (H&E stain) and immunohistochemistry (anti-EVM135 stain). Original magnifications are indicated. Data
correspond to 5 mice per group the SEM and are representative of two independent experiments. *, P 0.05; **, P 0.01; ***, P 0.001.
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munizedmice, the few necrotic foci in TSYKFESV- or SIFRFLNI-
immunized mice had a mononuclear cell infiltrate. Furthermore,
at 7 dpi very few areas in the livers of TSYKFESV- or SIFRLNI-
immunized mice, but most of the livers of SIINFEKL-immunized
mice, were stained with antisera to the structural ECTV protein
EVM135 (Fig. 5E). Thus, if productive, immunization with ID
and SD ECTV peptides protects from lethal mousepox infection
by controlling virus replication and liver damage.
NK cells are no longer required for resistance to mousepox
following effective peptide-DC immunization. Because the ef-
fector mechanisms of CD8 T cells and NK cells overlap, we next
tested whether NK cells are dispensable for protection when anti-
ECTV memory CD8 T cells are present. B6 mice were immu-
nized with TSYKFESV-DC, which resulted in a significant in-
crease in the frequency of CD8 T cells that stained with Kb-TSY
KFESV, as measured 4 weeks after booster immunization (Fig. 6A
and B). At 6 to 8 weeks postboost, TSYKFESV-DC-immunized
and control unimmunized B6 mice were depleted of NK cells and
were challenged with ECTV 1 day later. Eighty percent of TSYKF
ESV-DC-immunized mice survived, while all controls died (Fig.
6C). Thus, memory CD8 T cells of single specificity significantly
protected mice from lethal mousepox in the absence of NK cells.
DISCUSSION
In this study, we have demonstrated that memory CD8 T cells of
single specificity induced by immunization with DCs pulsed with
viral peptides protect from an acute lethal viral disease. Further-
more, we showed that CD8 T cells directed to the ID as well as to
those SD determinants that were effective at inducing a significant
CD8 T cell response upon DC-peptide immunization were
highly protective. Moreover, we showed that protection can be
achieved even in the absence of NK cells, which are essential for
resistance to primary ECTV infection.
Other laboratories have previously studied the differential pro-
tective abilities of memory CD8 T cells specific for single ID or
SD determinants during LCMV infection (20, 28, 29, 34, 41, 44,
49–51, 53, 56). However, the pathogenesis of LCMV is very differ-
ent from that of ECTV. Natural LCMV infection in the mouse
occurs in utero and results in a chronic infection rather than an
acute disease (4). Depending on the dose, route, and clone, exper-
imental intraperitoneal (i.p.) or i.v. infection results in transient
acute or chronic infection without major symptoms and causes
fatal meningitis only after intracerebral inoculation.
Somewhat analogous studies have also been performed follow-
ing infection with respiratory viruses. For example, Fu et al. gen-
erated a DNA construct encoding full-length NP with two muta-
tions (NPmut) that eliminated the ID determinant NP147-155
from influenza virus A/PR/8/34. This allowed for the detection of
the immunorecessive determinant NP218-226 (19). NP218-226
behaves as a typical immunorecessive determinant in that specific
CD8 T cell response, which can be detected only when the ID
determinant is absent during priming (39, 40, 42). BALB/c mice
were immunized intramuscularly with NPmut DNA and were
protected against cross-strain challenge with A/HK/68 (H3N2).
Also, Cole et al. demonstrated that the hierarchy of CD8 T cell
determinants recognized in Sendai virus can be selectively altered
by immunization against an SD determinant, with the resulting
CD8 T cell response following virus challenge directed predom-
inantly to the subdominant determinant (8). In addition, Kast et
al. showed that peptide immunization with the ID peptide of Sen-
dai virus protected mice from a lethal challenge (27). In these
experiments, protection conferred by memory CD8 T cells spe-
cific for an SD determinant was not assessed. These studies dif-
fered fromours because, different fromECTV infection, influenza
and Sendai viruses produce disease by replicating at the primary
site of infection rather than by spreading systemically. Moreover,
we examined protection by CD8 T cells against subdominant
rather than immunorecessive determinants, and we found that
the response to the ID determinant was not abrogated in the pres-
ence of memory cells to the SD determinant.
Regarding infection with the related OPV VACV, studies of
DNA vaccines containing ID or SD determinants from simian or
human immunodeficiency virus showed a reduction in virus titers
in ovaries of mice infected i.p. with recombinant VACV express-
ing the relevant determinants (24, 33). Snyder et al. showed pro-
tection against lethal secondary intranasal (i.n.) VACV challenge
in HLA-A2 transgenic mice by vaccination with an MHC-I-re-
stricted T cell determinant. However, mice with a memory CD8
T cell response to a single determinant did not have complete
protection, as somemice lost weight and somemice died. This did
not occur in mice previously immunized with the whole virus
(46). Cornberg et al. showed that VACV-E7R-specific memory
FIG 6 Memory CD8 T cells induced by peptide-DC immunization protect
mice against lethal mousepox infection in the absence of NK cells. B6 mice
were immunized with peptide-pulsed DCs. (A) Representative data for the
percentage of Kb-TSYKFESV-positive CD8 in PBMCs from naïve B6mice or
B6 mice vaccinated with TSYKFESV-DC. (B) Column graphs correspond to
summary data presented in the panel A flow cytometry plots for frequencies of
CD8 cells that were Kb-TSYKFESV. Data correspond to 3 independent
experiments ( SEM; n
 7 for naïve mice and n
 15 for TSYKFESV-vacci-
nated mice). (C) Survival of naïve and TSYKFESV-DC-immunized B6 mice
that were depleted of NK cells with the PK136 monoclonal antibody i.p. and
challenged with ECTV. Data correspond to 2 independent experiments 
SEM for naïve (n 
 8) and TSYKFESV-immunized (n 
 10) mice. ***, P 
0.001.
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CD8 T cells reduced viral load in the fat pads of mice following a
nonlethal dose of VACV inoculated i.p. Previously, we showed
variable levels of protection against i.n. VACV challenge in mice
immunized 12 days earlier with synthetic SD determinants (37).
In agreement, here we also have shown that immunization against
the SD epitopes KSYNYMLL and SIFRFLNI resulted in high fre-
quencies of peptide-specific CD8 T cells and very strong protec-
tion. On the other hand, immunization with ITYRFYLI- or STLN
FNNL-pulsed DCs was not effective at inducingmemory CD8 T
cells, and protection was almost nil even though their affinity for
MHC-I is very high,6 and12 nM, respectively (37). Of inter-
est, while in this study ITYRFYLI and STLNFNNL were very poor
immunogens, they were immunogenic and protective against
VACV in our previous report (37). At this point we can only
speculate about the reasons why DC immunization failed to in-
duce protective responses to these peptides. A major difference
with the previous report is that VACV is not a natural pathogen of
the mouse, replicating poorly in this host. In addition, i.n. VACV
infection ismainly a local infection that produces pneumonia (31,
35), while footpad infection with ECTV causes systemic disease
following lympho-hematogenous spread (4). As we have previ-
ously shown, a major mechanism whereby memory CD8 T cells
protect from mousepox is by curbing lympho-hematogenous
spread. Another difference between the two studies is that here we
used DC-peptide immunization and analyzed protection at 6 to 8
weeks after immunization, while in the previous report we exam-
ined protection by virus-specific CD8 T cells at 12 days postim-
munization with peptide in incomplete Freund adjuvant (IFA)
and with an MHC-II helper peptide. The time of challenge and
methods of immunization may have been responsible for the dif-
ferences observed. For example, the challenge with ECTV was
performed during the memory phase of the response, while the
challenge with VACV was done when the CD8 T cells were still
effectors and when IFA inflammatory signals may have still been
present at the time of challenge. It is also possible that DC immu-
nization failed to selectively induce responses to some peptides,
even though they have high affinity for MHC-I. In support, we
have been unable to induce responses to the influenza virus
A/PR8/34 NP immunodominant epitope ASNENMEM by DC
immunization, even though it has an 8 nM affinity for Db (45).
DCs have an endopeptidase activity at their plasma membrane
that has been shown to degrade the Kb-restricted tyrosinase
epitope YMDGTMSQV, precluding its recognition by CD8 T
cells (2). Thus, it is possible that, similar to YMDGTMSQV, pep-
tides such as ITYRFYLI, STLNFNNL, andASNENMETM, but not
the immunogenic peptides, are unsuitable for DC immunization
because they are preferentially degraded at the surface of DCs.
Another possibility is that, despite their high affinity for MHC-I,
the half-lives of the peptide–MHC-I complexes at the surface of
cells is shorter for the nonimmunogenic than the immunogenic
peptides. As an example, the half-life of Db-ASNENMETM at the
cell surface is 6 h 15min, quite shorter than that of TGICNQNII (9
h 30 min), another high-affinity NP peptide (45).
While normally resistant to footpad infection, B6mice infected
with ECTV i.n. succumbwith respiratory complications. Relevant
to our studies, Tscharke et al. reported that B6 mice immunized
with splenic DCs pulsed with TSYKFESV were partially protected
from i.n. challenge with ECTV (48). Those authors suggested that
the lack of complete protection could have beendue to insufficient
numbers of TSYKFESV-specific CD8 T cells induced by their
method of immunization, and they indicated that there may have
been at least 50-fold fewer TSYKFESV-specific CD8 T cells
than with VACV infection. In support of this view, our prime-
boost method of immunization resulted in strong responses to
some but not all the peptides. We observed complete protection
only when the frequency of memory CD8 T cells was high. In
agreement with our findings, West et al. demonstrated that a high
frequency (105) of virus-specific memory CD8 T cells from P14
transgenic mice were able to rapidly reduce or clear LCMV clone
13 virus (55). Thus, independent of the reason for the inability of
ITYRFYLI- and STLNFNNL-pulsed DCs to induce a response,
our data suggest that protection strongly correlates with produc-
tive immunization and that the immunogenicity of a peptide may
vary with the method of immunization. Hence, when designing
vaccines, it is important to determine the efficiency of CD8T cell
induction by the different determinants with the specific immu-
nization method.
Different from any of the other studies, we also analyzed the
primary CD8 T cell responses to the ID and SD determinants in
mice with preexisting memory CD8 T cells specific for the ID or
an SD determinant. Interestingly, the SIFRFLNI SD response was
undetectable inmice immune to the IDTSYKFESV.However, the
presence of memory CD8 T cells to SD SIFRFLNI did not over-
ride the ID response to TSYKFESV, suggesting that these primary
effectors could contribute to the protection.
We previously showed that NK cells migrate to the D-LN of
ECTV-infected mice and use perforin and IFN--dependent
mechanisms to reduce virus spread (10). We have more recently
shown that B6.D2-D6 mice are susceptible to mousepox because
they lack CD94, resulting in deficient control of ECTV byNK cells
(11). Our finding that memory CD8 T cells protect B6.D2-D6
frommousepox provided a first line of evidence that NK cells may
no longer be required for resistance to mousepox when memory
CD8T cells are present.However, a final conclusion could not be
drawn because in B6.D2-D6, NK cells still migrate to the D-LN
and produce IFN- following ECTV infection (11). Thus, our
results showing that B6 mice immunized with DC-TSYKFESV
remain resistant to mousepox after NK cell depletion definitively
demonstrate that NK cells are not required when protectivemem-
ory CD8 T cells are present.
In summary, our study provides uswith a better understanding
of the mechanisms of acquired protection to highly infectious
OPV. In addition, because ECTV spreads through the lympho-
hematogenous route, our findings may be relevant for the many
unrelated viruses that spread via this route (17, 52).Moreover, our
work contributes to the efforts of rational vaccine development by
providing information about mechanisms of acquired protection
thatmay be applicable to other pathogenic viruses that cause acute
or chronic viral diseases.
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